Current Insights and Future Directions of Li-Fraumeni Syndrome

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Oct 15

PMID 39404911

Authors

Mohammad-Salar Hosseini

Affiliations

Soon will be listed here.

Abstract

Li-Fraumeni syndrome is a rare yet serious hereditary cancer predisposition syndrome, marked by a significant early-life increased risk of developing cancer. Primarily caused by germline mutations in the TP53 tumor suppressor gene, Li-Fraumeni syndrome is associated with a wide range of malignancies. Clinical management of Li-Fraumeni syndrome could be challenging, especially the lifelong surveillance and follow-up of patients which requires a multidisciplinary approach. Emerging insights into the molecular and clinical basis of Li-Fraumeni syndrome, coupled with advances in genomic technologies and targeted therapies, offer promise in optimizing risk assessment, early detection, and treatment strategies tailored to the unique clinical and molecular profiles of affected individuals. This review discusses Li-Fraumeni syndrome in more depth, reviewing molecular, genomic, epidemiological, clinical, and therapeutic aspects of this disease.

References

Li J, Xiao S, Shi F, Song H, Wu J, Zheng D . Arsenic trioxide extends survival of Li-Fraumeni syndrome mimicking mouse. Cell Death Dis. 2023; 14(11):783. PMC: 10687230. DOI: 10.1038/s41419-023-06281-2. View

Giavedoni P, Ririe M, Carrera C, Puig S, Malvehy J . Familial Melanoma Associated with Li-Fraumeni Syndrome and Atypical Mole Syndrome: Total-body Digital Photography, Dermoscopy and Confocal Microscopy. Acta Derm Venereol. 2017; 97(6):720-723. DOI: 10.2340/00015555-2639. View

Sim G, Radvanyi L . The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014; 25(4):377-90. DOI: 10.1016/j.cytogfr.2014.07.018. View

Reed D, Shokat K . Targeting osteosarcoma. Proc Natl Acad Sci U S A. 2014; 111(51):18100-1. PMC: 4280583. DOI: 10.1073/pnas.1420596111. View

Kuba M, Lester S, Bowman T, Stokes S, Taneja K, Garber J . Histopathologic features of breast cancer in Li-Fraumeni syndrome. Mod Pathol. 2020; 34(3):542-548. DOI: 10.1038/s41379-020-0610-4. View

Mai P, Best A, Peters J, DeCastro R, Khincha P, Loud J . Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016; 122(23):3673-3681. PMC: 5115949. DOI: 10.1002/cncr.30248. View

Chen L, Xu B, Long X, Gu J, Lou Y, Wang D . CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome. J Immunother Cancer. 2020; 8(1). PMC: 7213909. DOI: 10.1136/jitc-2019-000364. View

Zawacka J . p53 biology and reactivation for improved therapy in MDS and AML. Biomark Res. 2024; 12(1):34. PMC: 10936007. DOI: 10.1186/s40364-024-00579-9. View

Kumamoto T, Yamazaki F, Nakano Y, Tamura C, Tashiro S, Hattori H . Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol. 2021; 26(12):2161-2178. PMC: 8595164. DOI: 10.1007/s10147-021-02011-w. View

10.

Smith H, Southgate H, Tweddle D, Curtin N . DNA damage checkpoint kinases in cancer. Expert Rev Mol Med. 2020; 22:e2. DOI: 10.1017/erm.2020.3. View

11.

Grill S, Ramser J, Hellebrand H, Pfarr N, Boxberg M, Brambs C . TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge. Arch Gynecol Obstet. 2020; 303(6):1557-1567. PMC: 8087555. DOI: 10.1007/s00404-020-05883-x. View

12.

Evans D, Huson S, Birch J . Malignant peripheral nerve sheath tumours in inherited disease. Clin Sarcoma Res. 2012; 2(1):17. PMC: 3499223. DOI: 10.1186/2045-3329-2-17. View

13.

Naseri A, Sanaie S, Hamzehzadeh S, Seyedi-Sahebari S, Hosseini M, Gholipour-Khalili E . Metformin: new applications for an old drug. J Basic Clin Physiol Pharmacol. 2022; 34(2):151-160. DOI: 10.1515/jbcpp-2022-0252. View

14.

Shin S, Dodd-Eaton E, Peng G, Bojadzieva J, Chen J, Amos C . Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts. Cancer Res. 2019; 80(2):354-360. PMC: 6980689. DOI: 10.1158/0008-5472.CAN-19-0728. View

15.

Petr E, Else T . Genetic predisposition to endocrine tumors: Diagnosis, surveillance and challenges in care. Semin Oncol. 2016; 43(5):582-590. DOI: 10.1053/j.seminoncol.2016.08.007. View

16.

Natsume H, Szczepaniak K, Yamada H, Iwashita Y, Gedek M, Suto J . Non-CpG sites preference in G:C > A:T transition of TP53 in gastric cancer of Eastern Europe (Poland, Romania and Hungary) compared to East Asian countries (China and Japan). Genes Environ. 2023; 45(1):1. DOI: 10.1186/s41021-022-00257-y. View

17.

McEvoy M, Robison N, Manley P, Yock T, Konopka K, Brown R . Successful Treatment of Recurrent Li-Fraumeni Syndrome-related Choroid Plexus Carcinoma. J Pediatr Hematol Oncol. 2017; 39(8):e473-e475. PMC: 5657537. DOI: 10.1097/MPH.0000000000000965. View

18.

Wei J, Xiao M, Mao Z, Wang N, Cao Y, Xiao Y . Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. Signal Transduct Target Ther. 2022; 7(1):101. PMC: 8995369. DOI: 10.1038/s41392-022-00924-0. View

19.

Deniger D, Pasetto A, Robbins P, Gartner J, Prickett T, Paria B . T-cell Responses to "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. Clin Cancer Res. 2018; 24(22):5562-5573. PMC: 6239943. DOI: 10.1158/1078-0432.CCR-18-0573. View

20.

Zhong W, Xu X, Zhu Z, Yang L, Du H, Xia Z . Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma. Int J Oncol. 2018; 52(5):1528-1538. PMC: 5873833. DOI: 10.3892/ijo.2018.4299. View